AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio" or the "Company") (NASDAQ: ANPC) has announced the pricing of its initial public offering of 1,333,360 American depositary shares ("ADSs") at US$12.00 per ADS. This amounts to a total offering size of approximately US$16.0 million. Each ADS represents one Class A ordinary share of the Company. The ADSs are expected to start trading on the Nasdaq Global Market on January 30, 2020, under the ticker symbol "ANPC."
The underwriters of the offering have been granted an option to purchase up to an additional 200,004 ADSs at the initial public offering price, within 30 days from the date of the final prospectus, to cover over-allotments. WestPark Capital, Inc. and Univest Securities, LLC are acting as joint bookrunners of this offering and as the representatives of the underwriters.
AnPac Bio's registration statement relating to the offering has been filed with and declared effective by the United States Securities and Exchange Commission. It is important to note that this press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein. Furthermore, there shall be no sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
This offering of the securities is made only by means of a prospectus forming part of the effective registration statement. Interested parties may obtain a copy of the final prospectus relating to the offering by contacting WestPark Capital, Inc. or Univest Securities, LLC.
AnPac Bio is a biotechnology company focused on early cancer screening and detection. The company operates two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States. AnPac Bio conducts a range of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to a market research report by Frost & Sullivan, AnPac Bio is ranked second worldwide among companies offering next-generation early cancer screening and detection technologies, based on the number of clinical samples for cancer screening and detection. The company's CDA technology and platform have shown high sensitivity and specificity in detecting the risk of over 20 different cancer types.
For more information about AnPac Bio, please visit their website: https://www.anpacbio.com
For investor and media inquiries, please contact:
Phil Case, Marketing and Investor Relations
Phone: +1-267-810-6776 (US)
Email: [email protected]
Ascent Investor Relations LLC
Tina Xiao, President
Phone: +1-917-609-0333 (US)
Email: [email protected]
SOURCE AnPac Bio-Medical Science Co., Ltd.